Australia is anticipating the introduction of Retatrutide, a novel medication by Novo Nordisk. This dual-action drug, targeting both GLP-1 and GIP receptors, presents remarkable efficacy in clinical trials, suggesting https://janaqtih184584.wikissl.com/2512128/this_new_drug_retatrutide_australia_a_promising_solution_for_weight_management